Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

20151,311 citationsJournal Articlebronze Open Access

Authors

Sagar Lonial · Piedmont Reference Center for Epidemiology and Cancer Prevention

Meletios Α. Dimopoulos · National and Kapodistrian University of Athens

Antonio Palumbo · Azienda Ospedaliero Universitaria San Giovanni Battista

Darrell White · Dalhousie University

Sebastian Grosicki · Medical University of Silesia

Ivan Špıčka · Charles University

Adam Walter‐Croneck

Abstract

Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).

Topics & Keywords

Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis Protein Degradation and Inhibitors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 7, pp. 621-631

DOI: 10.1056/nejmoa1505654

Field-Weighted Citation Impact: 112.68